The latest update is out from Surrozen ( (SRZN) ).
On March 24, 2025, Surrozen, Inc. entered into a Securities Purchase Agreement with institutional and accredited investors for a two-tranche private placement of shares and warrants, raising approximately $76.4 million in the first tranche. The second tranche, contingent on FDA clearance of an Investigational New Drug Application by October 31, 2026, could bring an additional $98.6 million. Additionally, Tim Kutzkey was appointed as a Class I director on March 26, 2025, bringing extensive experience in biotechnology and venture capital.
More about Surrozen
Surrozen, Inc. operates in the biotechnology industry, focusing on developing therapeutic antibodies. The company collaborates with other firms to discover treatments for diseases such as idiopathic pulmonary fibrosis.
YTD Price Performance: -20.07%
Average Trading Volume: 29,336
Technical Sentiment Signal: Sell
Current Market Cap: $37.02M
Find detailed analytics on SRZN stock on TipRanks’ Stock Analysis page.